PARTNER 3 Trial - Aortic Valve-in-Valve
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Edwards Lifesciences
- Study ID
- NCT03003299
- Status
- Recruiting
Conditions
- Aortic Stenosis
- Aortic Stenosis, Severe
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Edwards SAPIEN 3/SAPIEN 3 Ultra THV — DEVICEEdwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
Study Details
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Key Dates
- Start date
- Jan 5, 2017
- Status verified
- May 2024
- Primary completion
- Jan 31, 2033
- Completion
- Apr 30, 2038
Study Design
- Enrollment
- 125 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: TAVR - Failing surgical or transcatheter valvePatients with a failing surgical or transcatheter bioprosthetic valve will undergo transcatheter aortic valve replacement (TAVR).
Primary Outcome Measure
Safety and Effectiveness - Non-hierarchical composite of all-cause mortality and stroke [ Time Frame: 1 year ]
Central Contacts
- Edwards THV Clinical Affairs(949) 250-2500
Locations (50)
Find similar trials in Phoenix, AZ
By research site
Banner University Medical Center· Phoenix, AZUniversity of California Los Angeles· Los Angeles, CASutter Medical Center· Sacramento, CAKaiser Permanente San Francisco· San Francisco, CAStanford University Medical Center· Stanford, CAUC Health Northern Colorado/Medical Center of the Rockies· Loveland, CO
Related Studies
- Comparative Imaging Assessment of Valvular Heart DiseaseRecruiting · The Cleveland Clinic · Cleveland, Ohio
- The HALT Biomarker StudyPHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve ReplacementRecruiting · University of British Columbia · Huntsville, Alabama
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisPHASE2 · Recruiting · Novartis Pharmaceuticals · Huntsville, Alabama